Evidence map›Paper›PMID 33566819›Full record

ArticlePLoS computational biology2021

miRNA normalization enables joint analysis of several datasets to increase sensitivity and to reveal novel miRNAs differentially expressed in breast cancer.

Shay Ben-Elazar, Miriam Ragle Aure, Kristin Jonsdottir, Suvi-Katri Leivonen, Vessela N Kristensen, Emiel A M Janssen, Kristine Kleivi Sahlberg, Ole Christian Lingjærde, Zohar Yakhini

Abstract read
In one paragraph

Article in PLoS computational biology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Shay Ben-ElazarSchool of Computer Science, Tel-Aviv University, Tel-Aviv, Israel.ORCID 0000-0002-1461-9168
Miriam Ragle AureDepartment of Cancer Genetics, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.ORCID 0000-0001-7739-4982
Kristin JonsdottirDepartment of Pathology, Stavanger University Hospital, Stavanger, Norway.ORCID 0000-0001-9772-925X
Suvi-Katri LeivonenHelsinki University Hospital Comprehensive Cancer Centre and University of Helsinki, Helsinki, Finland.ORCID 0000-0003-3224-0757
Vessela N KristensenDepartment of Cancer Genetics, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.ORCID 0000-0001-5012-7438
Emiel A M JanssenDepartment of Pathology, Stavanger University Hospital, Stavanger, Norway.ORCID 0000-0002-7760-5396
Kristine Kleivi SahlbergDepartment of Cancer Genetics, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.
Ole Christian LingjærdeDepartment of Cancer Genetics, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.
Zohar YakhiniDepartment of Computer Science, Interdisciplinary Center, Herzliya, Israel.ORCID 0000-0002-0420-5412

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Different miRNA profiling protocols and technologies introduce differences in the resulting quantitative expression profiles. These include differences in the presence (and measurability) of certain miRNAs. We present and examine a method based on quantile normalization, Adjusted Quantile Normalization (AQuN), to combine miRNA expression data from multiple studies in breast cancer into a single joint dataset for integrative analysis. By pooling multiple datasets, we obtain increased statistical power, surfacing patterns that do not emerge as statistically significant when separately analyzing these datasets. To merge several datasets, as we do here, one needs to overcome both technical and batch differences between these datasets. We compare several approaches for merging and jointly analyzing miRNA datasets. We investigate the statistical confidence for known results and highlight potential new findings that resulted from the joint analysis using AQuN. In particular, we detect several miRNAs to be differentially expressed in estrogen receptor (ER) positive versus ER negative samples. In addition, we identify new potential biomarkers and therapeutic targets for both clinical groups. As a specific example, using the AQuN-derived dataset we detect hsa-miR-193b-5p to have a statistically significant over-expression in the ER positive group, a phenomenon that was not previously reported. Furthermore, as demonstrated by functional assays in breast cancer cell lines, overexpression of hsa-miR-193b-5p in breast cancer cell lines resulted in decreased cell viability in addition to inducing apoptosis. Together, these observations suggest a novel functional role for this miRNA in breast cancer. Packages implementing AQuN are provided for Python and Matlab: https://github.com/YakhiniGroup/PyAQN.

Indexed as

Gene Expression ProfilingGene Expression Regulation, NeoplasticAlgorithmsBiomarkersBiomarkers, TumorBreast NeoplasmsCell Line, TumorComputer SimulationEstrogen Receptor alphaFemaleHumansMCF-7 CellsMicroRNAsOligonucleotide Array Sequence AnalysisProgramming LanguagesRNA, MessengerBiomarkersBiomarkers, TumorESR1 protein, humanEstrogen Receptor alphaMicroRNAsMIRN193 microRNA, humanRNA, Messenger

Identifiers

PMID33566819
PMCPMC7901788

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.